 Chad Rusthoven
Concepts (283)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 42 | 2025 | 399 | 11.410 |
Why?
| | Lung Neoplasms | 63 | 2025 | 2664 | 8.180 |
Why?
| | Brain Neoplasms | 46 | 2025 | 1329 | 7.930 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 40 | 2025 | 1189 | 7.760 |
Why?
| | Small Cell Lung Carcinoma | 17 | 2024 | 122 | 7.070 |
Why?
| | Cranial Irradiation | 15 | 2024 | 85 | 3.400 |
Why?
| | Prostatic Neoplasms | 9 | 2016 | 978 | 1.790 |
Why?
| | Chemoradiotherapy | 13 | 2025 | 239 | 1.770 |
Why?
| | Radiotherapy, Adjuvant | 7 | 2022 | 222 | 1.710 |
Why?
| | Glioblastoma | 5 | 2019 | 353 | 1.360 |
Why?
| | ErbB Receptors | 7 | 2024 | 635 | 1.330 |
Why?
| | Neoplasm Staging | 26 | 2022 | 1471 | 1.280 |
Why?
| | Radiotherapy | 6 | 2020 | 204 | 1.210 |
Why?
| | Aged | 62 | 2025 | 26153 | 1.030 |
Why?
| | Protein Kinase Inhibitors | 3 | 2024 | 981 | 1.000 |
Why?
| | Dacarbazine | 2 | 2017 | 100 | 0.970 |
Why?
| | Four-Dimensional Computed Tomography | 9 | 2025 | 38 | 0.930 |
Why?
| | Kaplan-Meier Estimate | 14 | 2019 | 969 | 0.920 |
Why?
| | Humans | 121 | 2025 | 145474 | 0.920 |
Why?
| | Stomach Neoplasms | 2 | 2017 | 128 | 0.910 |
Why?
| | Aged, 80 and over | 32 | 2025 | 8333 | 0.870 |
Why?
| | Neoplasm Grading | 8 | 2024 | 310 | 0.850 |
Why?
| | Proportional Hazards Models | 12 | 2019 | 1327 | 0.840 |
Why?
| | Treatment Outcome | 28 | 2025 | 11772 | 0.830 |
Why?
| | Middle Aged | 58 | 2025 | 36215 | 0.810 |
Why?
| | Oncogene Addiction | 1 | 2023 | 6 | 0.770 |
Why?
| | Databases, Factual | 12 | 2019 | 1490 | 0.770 |
Why?
| | Retrospective Studies | 40 | 2025 | 17291 | 0.730 |
Why?
| | Receptor Protein-Tyrosine Kinases | 4 | 2022 | 231 | 0.730 |
Why?
| | Melanoma | 7 | 2025 | 759 | 0.720 |
Why?
| | Vascular Neoplasms | 2 | 2013 | 18 | 0.710 |
Why?
| | Combined Modality Therapy | 15 | 2020 | 1266 | 0.690 |
Why?
| | Sarcoma | 3 | 2015 | 207 | 0.680 |
Why?
| | Pneumonectomy | 3 | 2020 | 167 | 0.670 |
Why?
| | Glioma | 3 | 2020 | 429 | 0.670 |
Why?
| | Meningioma | 4 | 2024 | 88 | 0.660 |
Why?
| | Meningeal Neoplasms | 4 | 2024 | 95 | 0.660 |
Why?
| | Neoadjuvant Therapy | 6 | 2018 | 465 | 0.660 |
Why?
| | Neurocognitive Disorders | 1 | 2020 | 33 | 0.630 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2022 | 117 | 0.610 |
Why?
| | Radiation Oncology | 3 | 2022 | 82 | 0.610 |
Why?
| | Male | 57 | 2025 | 72842 | 0.610 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2023 | 431 | 0.610 |
Why?
| | Antineoplastic Agents, Alkylating | 2 | 2017 | 74 | 0.600 |
Why?
| | Proto-Oncogene Proteins | 1 | 2023 | 624 | 0.600 |
Why?
| | Prognosis | 18 | 2025 | 4316 | 0.600 |
Why?
| | Survival Analysis | 10 | 2020 | 1374 | 0.590 |
Why?
| | Carcinoma, Renal Cell | 4 | 2023 | 230 | 0.570 |
Why?
| | Astrocytoma | 2 | 2020 | 130 | 0.550 |
Why?
| | Radiotherapy, Conformal | 3 | 2017 | 74 | 0.550 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 7 | 2025 | 149 | 0.540 |
Why?
| | Carcinoma | 2 | 2017 | 225 | 0.540 |
Why?
| | Adult | 42 | 2025 | 40777 | 0.530 |
Why?
| | SEER Program | 9 | 2018 | 229 | 0.520 |
Why?
| | Hospitals, Low-Volume | 1 | 2017 | 26 | 0.520 |
Why?
| | Female | 57 | 2025 | 78844 | 0.520 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2017 | 21 | 0.510 |
Why?
| | Hospitals, High-Volume | 1 | 2017 | 50 | 0.510 |
Why?
| | Survival Rate | 13 | 2025 | 2090 | 0.500 |
Why?
| | Kidney Neoplasms | 4 | 2023 | 413 | 0.500 |
Why?
| | Thymoma | 1 | 2017 | 37 | 0.500 |
Why?
| | Thymus Neoplasms | 1 | 2017 | 30 | 0.500 |
Why?
| | Uterine Cervical Neoplasms | 5 | 2019 | 268 | 0.490 |
Why?
| | Liver Neoplasms | 1 | 2023 | 776 | 0.480 |
Why?
| | Follow-Up Studies | 15 | 2025 | 5423 | 0.460 |
Why?
| | Lymph Nodes | 3 | 2016 | 503 | 0.450 |
Why?
| | Hippocampus | 2 | 2021 | 971 | 0.450 |
Why?
| | Neoplasm Metastasis | 6 | 2018 | 688 | 0.440 |
Why?
| | Antineoplastic Agents | 3 | 2023 | 2214 | 0.440 |
Why?
| | Oligodendroglioma | 1 | 2014 | 15 | 0.430 |
Why?
| | Postoperative Care | 1 | 2017 | 286 | 0.430 |
Why?
| | Radiotherapy Dosage | 11 | 2019 | 288 | 0.430 |
Why?
| | Multivariate Analysis | 6 | 2019 | 1547 | 0.420 |
Why?
| | Radiotherapy, Intensity-Modulated | 6 | 2019 | 142 | 0.420 |
Why?
| | Observational Studies as Topic | 1 | 2015 | 133 | 0.420 |
Why?
| | Central Nervous System Neoplasms | 3 | 2023 | 177 | 0.410 |
Why?
| | Propensity Score | 6 | 2018 | 377 | 0.410 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2022 | 423 | 0.410 |
Why?
| | Checklist | 1 | 2015 | 110 | 0.400 |
Why?
| | Adenocarcinoma | 2 | 2019 | 925 | 0.390 |
Why?
| | Immunotherapy | 5 | 2024 | 666 | 0.380 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2019 | 549 | 0.380 |
Why?
| | Pulmonary Ventilation | 5 | 2021 | 82 | 0.360 |
Why?
| | Prospective Studies | 11 | 2024 | 8057 | 0.360 |
Why?
| | Breast Neoplasms | 5 | 2024 | 2382 | 0.350 |
Why?
| | United States | 22 | 2019 | 16098 | 0.350 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2024 | 1149 | 0.340 |
Why?
| | Disease-Free Survival | 4 | 2019 | 767 | 0.330 |
Why?
| | Registries | 4 | 2018 | 2406 | 0.330 |
Why?
| | Magnetic Resonance Imaging | 4 | 2023 | 3904 | 0.320 |
Why?
| | Aorta | 1 | 2013 | 440 | 0.320 |
Why?
| | Radiation Pneumonitis | 2 | 2021 | 31 | 0.310 |
Why?
| | Embolism | 1 | 2010 | 48 | 0.310 |
Why?
| | Patient Reported Outcome Measures | 2 | 2025 | 497 | 0.310 |
Why?
| | Hysterectomy | 3 | 2019 | 138 | 0.300 |
Why?
| | Margins of Excision | 2 | 2019 | 50 | 0.280 |
Why?
| | Insurance Coverage | 4 | 2018 | 244 | 0.280 |
Why?
| | Disease Progression | 7 | 2023 | 2864 | 0.280 |
Why?
| | Young Adult | 16 | 2025 | 14218 | 0.270 |
Why?
| | Central Nervous System | 4 | 2023 | 282 | 0.270 |
Why?
| | Lung | 8 | 2024 | 4106 | 0.260 |
Why?
| | Aorta, Thoracic | 1 | 2010 | 286 | 0.260 |
Why?
| | Blood Vessel Prosthesis Implantation | 1 | 2010 | 228 | 0.260 |
Why?
| | Prostate-Specific Antigen | 4 | 2016 | 161 | 0.250 |
Why?
| | Quality of Life | 4 | 2025 | 3204 | 0.240 |
Why?
| | Clinical Decision-Making | 2 | 2022 | 363 | 0.240 |
Why?
| | Analysis of Variance | 4 | 2017 | 1300 | 0.240 |
Why?
| | Neoplasms | 3 | 2018 | 2906 | 0.230 |
Why?
| | Time Factors | 6 | 2019 | 7123 | 0.230 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 1963 | 0.230 |
Why?
| | Gastrectomy | 2 | 2017 | 166 | 0.230 |
Why?
| | Mediastinal Neoplasms | 2 | 2016 | 53 | 0.220 |
Why?
| | Lymphatic Metastasis | 2 | 2018 | 331 | 0.220 |
Why?
| | Organs at Risk | 3 | 2019 | 37 | 0.210 |
Why?
| | Carbazoles | 1 | 2024 | 53 | 0.210 |
Why?
| | Insurance, Health | 2 | 2018 | 310 | 0.210 |
Why?
| | Acrylamides | 1 | 2024 | 74 | 0.200 |
Why?
| | Genital Neoplasms, Female | 1 | 2025 | 99 | 0.200 |
Why?
| | Necrosis | 3 | 2022 | 244 | 0.200 |
Why?
| | Neoplasm Invasiveness | 2 | 2017 | 506 | 0.200 |
Why?
| | Skin Neoplasms | 2 | 2025 | 849 | 0.200 |
Why?
| | Standard of Care | 2 | 2021 | 81 | 0.200 |
Why?
| | Aniline Compounds | 1 | 2024 | 120 | 0.200 |
Why?
| | Androgen Antagonists | 4 | 2016 | 91 | 0.200 |
Why?
| | Salvage Therapy | 1 | 2024 | 165 | 0.190 |
Why?
| | Piperidines | 1 | 2024 | 222 | 0.190 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2016 | 641 | 0.180 |
Why?
| | Cell Differentiation | 1 | 2010 | 2046 | 0.180 |
Why?
| | Neurosurgery | 1 | 2022 | 41 | 0.180 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2025 | 258 | 0.180 |
Why?
| | Medical Oncology | 3 | 2021 | 339 | 0.170 |
Why?
| | Radiation Injuries | 1 | 2022 | 149 | 0.170 |
Why?
| | Adolescent | 12 | 2021 | 22529 | 0.170 |
Why?
| | Regression Analysis | 3 | 2019 | 1001 | 0.160 |
Why?
| | Pyrimidines | 1 | 2024 | 530 | 0.160 |
Why?
| | Healthcare Disparities | 2 | 2018 | 735 | 0.160 |
Why?
| | Indoles | 1 | 2024 | 507 | 0.160 |
Why?
| | Internationality | 1 | 2021 | 156 | 0.160 |
Why?
| | Respiration | 4 | 2023 | 206 | 0.150 |
Why?
| | Cohort Studies | 4 | 2022 | 6013 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2019 | 198 | 0.150 |
Why?
| | Mutation | 4 | 2024 | 4075 | 0.150 |
Why?
| | Respiratory Function Tests | 2 | 2023 | 544 | 0.150 |
Why?
| | Diagnostic Imaging | 1 | 2022 | 337 | 0.150 |
Why?
| | Heart | 2 | 2020 | 626 | 0.140 |
Why?
| | Mastectomy, Segmental | 2 | 2017 | 107 | 0.140 |
Why?
| | Expert Testimony | 1 | 2019 | 42 | 0.140 |
Why?
| | Peritoneum | 1 | 2018 | 43 | 0.140 |
Why?
| | Neurologic Examination | 1 | 2019 | 132 | 0.140 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2018 | 44 | 0.140 |
Why?
| | Molecular Targeted Therapy | 1 | 2022 | 439 | 0.140 |
Why?
| | Brain | 3 | 2022 | 2947 | 0.140 |
Why?
| | Socioeconomic Factors | 3 | 2017 | 1323 | 0.140 |
Why?
| | Aquaporin 4 | 1 | 2019 | 101 | 0.140 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2018 | 30 | 0.140 |
Why?
| | Uncertainty | 1 | 2019 | 146 | 0.140 |
Why?
| | Re-Irradiation | 1 | 2018 | 9 | 0.140 |
Why?
| | Oxides | 1 | 2018 | 47 | 0.140 |
Why?
| | Knowledge Bases | 1 | 2018 | 28 | 0.140 |
Why?
| | Time-to-Treatment | 1 | 2020 | 251 | 0.130 |
Why?
| | Brachytherapy | 2 | 2016 | 132 | 0.130 |
Why?
| | Spinal Neoplasms | 1 | 2018 | 37 | 0.130 |
Why?
| | Patient Selection | 3 | 2019 | 738 | 0.130 |
Why?
| | CTLA-4 Antigen | 1 | 2018 | 105 | 0.130 |
Why?
| | Mesothelioma | 1 | 2018 | 51 | 0.130 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2018 | 69 | 0.130 |
Why?
| | Intersectoral Collaboration | 1 | 2018 | 64 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2019 | 274 | 0.130 |
Why?
| | Nervous System | 1 | 2017 | 69 | 0.130 |
Why?
| | Peritoneal Neoplasms | 1 | 2018 | 104 | 0.130 |
Why?
| | Oncologists | 1 | 2018 | 47 | 0.130 |
Why?
| | Professional Competence | 1 | 2018 | 91 | 0.130 |
Why?
| | Hyperthermia, Induced | 1 | 2018 | 120 | 0.130 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 61 | 0.130 |
Why?
| | Risk Factors | 5 | 2019 | 10885 | 0.120 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 200 | 0.120 |
Why?
| | Functional Laterality | 1 | 2017 | 240 | 0.120 |
Why?
| | Mortality | 1 | 2019 | 378 | 0.120 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2016 | 56 | 0.120 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 265 | 0.120 |
Why?
| | Lung Diseases | 1 | 2023 | 780 | 0.120 |
Why?
| | Antibodies | 1 | 2018 | 397 | 0.120 |
Why?
| | Physician's Role | 1 | 2018 | 223 | 0.120 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 1581 | 0.120 |
Why?
| | Perioperative Care | 1 | 2018 | 231 | 0.110 |
Why?
| | Comorbidity | 2 | 2017 | 1661 | 0.110 |
Why?
| | Thoracic Neoplasms | 1 | 2015 | 39 | 0.110 |
Why?
| | Medically Uninsured | 1 | 2015 | 132 | 0.110 |
Why?
| | Cholangiocarcinoma | 1 | 2016 | 108 | 0.110 |
Why?
| | Positron-Emission Tomography | 2 | 2022 | 343 | 0.110 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2016 | 193 | 0.110 |
Why?
| | Bile Duct Neoplasms | 1 | 2016 | 131 | 0.110 |
Why?
| | Lymphoma, B-Cell | 1 | 2016 | 140 | 0.110 |
Why?
| | Marital Status | 1 | 2014 | 46 | 0.110 |
Why?
| | Myocardium | 1 | 2020 | 934 | 0.110 |
Why?
| | Cause of Death | 1 | 2017 | 470 | 0.110 |
Why?
| | Maytansine | 1 | 2014 | 18 | 0.110 |
Why?
| | Preoperative Care | 1 | 2017 | 380 | 0.100 |
Why?
| | Mastectomy | 1 | 2016 | 184 | 0.100 |
Why?
| | Brain Edema | 1 | 2014 | 62 | 0.100 |
Why?
| | Tumor Burden | 4 | 2019 | 325 | 0.100 |
Why?
| | Prostatectomy | 1 | 2014 | 94 | 0.100 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2015 | 193 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1443 | 0.090 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 588 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 1061 | 0.090 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 2 | 2023 | 104 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 2 | 2018 | 1371 | 0.090 |
Why?
| | Fiducial Markers | 1 | 2011 | 9 | 0.090 |
Why?
| | Medicaid | 1 | 2015 | 467 | 0.080 |
Why?
| | Age Factors | 2 | 2017 | 3342 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2930 | 0.080 |
Why?
| | Perfusion | 2 | 2023 | 251 | 0.080 |
Why?
| | Biomarkers, Tumor | 1 | 2017 | 1321 | 0.080 |
Why?
| | Aortography | 1 | 2010 | 52 | 0.080 |
Why?
| | Blood Vessel Prosthesis | 1 | 2010 | 140 | 0.070 |
Why?
| | Movement | 1 | 2011 | 293 | 0.070 |
Why?
| | Vagina | 1 | 2011 | 203 | 0.070 |
Why?
| | Endometrial Neoplasms | 1 | 2011 | 205 | 0.070 |
Why?
| | Ultrasonography, Interventional | 1 | 2010 | 165 | 0.070 |
Why?
| | Sex Factors | 1 | 2014 | 2105 | 0.070 |
Why?
| | Prosthesis Design | 1 | 2010 | 354 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 992 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2019 | 1747 | 0.060 |
Why?
| | Immunohistochemistry | 1 | 2010 | 1716 | 0.060 |
Why?
| | Stents | 1 | 2010 | 564 | 0.060 |
Why?
| | Risk Assessment | 1 | 2015 | 3747 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2018 | 2769 | 0.050 |
Why?
| | Societies, Medical | 2 | 2018 | 899 | 0.050 |
Why?
| | Guideline Adherence | 2 | 2018 | 586 | 0.050 |
Why?
| | Child, Preschool | 2 | 2015 | 11853 | 0.040 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2022 | 161 | 0.040 |
Why?
| | Radiopharmaceuticals | 1 | 2022 | 205 | 0.040 |
Why?
| | Optic Nerve | 1 | 2021 | 67 | 0.040 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2022 | 223 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 477 | 0.040 |
Why?
| | Lymphopenia | 1 | 2019 | 62 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 6066 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2019 | 316 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2018 | 140 | 0.030 |
Why?
| | Neutropenia | 1 | 2019 | 154 | 0.030 |
Why?
| | Immune System | 1 | 2019 | 180 | 0.030 |
Why?
| | Gene Rearrangement | 1 | 2018 | 155 | 0.030 |
Why?
| | Radiation Dosage | 1 | 2019 | 193 | 0.030 |
Why?
| | Thoracic Vertebrae | 1 | 2018 | 82 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 428 | 0.030 |
Why?
| | Lymphocytes | 1 | 2019 | 376 | 0.030 |
Why?
| | History, 21st Century | 1 | 2018 | 222 | 0.030 |
Why?
| | Child | 2 | 2015 | 22707 | 0.030 |
Why?
| | Age Distribution | 1 | 2017 | 403 | 0.030 |
Why?
| | Genes, erbB-1 | 1 | 2016 | 21 | 0.030 |
Why?
| | Preoperative Period | 1 | 2017 | 149 | 0.030 |
Why?
| | Skin Ulcer | 1 | 2015 | 15 | 0.030 |
Why?
| | Papillomaviridae | 1 | 2016 | 116 | 0.030 |
Why?
| | Translocation, Genetic | 1 | 2016 | 119 | 0.030 |
Why?
| | Datasets as Topic | 1 | 2016 | 118 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2023 | 1505 | 0.030 |
Why?
| | Patient Preference | 1 | 2018 | 223 | 0.030 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2016 | 98 | 0.030 |
Why?
| | Spinal Cord | 1 | 2018 | 382 | 0.030 |
Why?
| | Rituximab | 1 | 2016 | 210 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2016 | 212 | 0.030 |
Why?
| | Pelvis | 1 | 2015 | 125 | 0.030 |
Why?
| | Prostate | 1 | 2015 | 158 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 1082 | 0.030 |
Why?
| | Colonic Neoplasms | 1 | 2016 | 257 | 0.030 |
Why?
| | Trastuzumab | 1 | 2014 | 118 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 740 | 0.020 |
Why?
| | Neutrophils | 1 | 2019 | 1124 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 639 | 0.020 |
Why?
| | Logistic Models | 1 | 2018 | 2134 | 0.020 |
Why?
| | Disease Management | 1 | 2017 | 653 | 0.020 |
Why?
| | Research Design | 1 | 2018 | 1137 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2016 | 344 | 0.020 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2011 | 39 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2953 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3623 | 0.020 |
Why?
| | Palliative Care | 1 | 2018 | 1020 | 0.020 |
Why?
| | Algorithms | 1 | 2017 | 1845 | 0.020 |
Why?
| | Radiography | 1 | 2011 | 852 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5904 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2015 | 6447 | 0.010 |
Why?
| | Infant | 1 | 2015 | 10077 | 0.010 |
Why?
|
|
Rusthoven's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|